3.46
-0.11 (-3.08%)
| Previous Close | 3.57 |
| Open | 3.52 |
| Volume | 1,259,535 |
| Avg. Volume (3M) | 2,008,542 |
| Market Cap | 571,730,240 |
| Price / Earnings (TTM) | 4.49 |
| Price / Sales | 1.82 |
| 52 Weeks Range | |
| Earnings Date | 9 Nov 2026 |
| Profit Margin | -10.18% |
| Operating Margin (TTM) | -25.64% |
| Diluted EPS (TTM) | -0.190 |
| Quarterly Revenue Growth (YOY) | -45.10% |
| Quarterly Earnings Growth (YOY) | -76.20% |
| Current Ratio (MRQ) | 3.34 |
| Operating Cash Flow (TTM) | 78.52 M |
| Levered Free Cash Flow (TTM) | 83.30 M |
| Return on Assets (TTM) | 12.03% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Ironwood Pharmaceuticals, Inc. | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -0.7 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | -0.5 |
| Relative Valuation | NA |
| Financial Health | 4.3 |
| Macro Environment | -0.3 |
| AI Insight | NA |
| AI Technical | NA |
| Weighted Average | -0.33 |
Select this tab to load the latest available analysis.
|
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Value |
| % Held by Insiders | 2.68% |
| % Held by Institutions | 97.41% |
No data within this time range.
No data within this time range.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |